X0306 4 2016-06-21 1 0001344413 Alexza Pharmaceuticals Inc. ALXA 0001612008 Kamemoto Edwin S C/O ALEXZA PHARMACEUTICALS, INC. 2091 STIERLIN COURT MOUNTAIN VIEW CA 94043 0 1 0 0 EVP, R&D, Regulatory & Quality Common Stock 2016-06-21 4 U 0 9112 D 0 D Stock Option (right to buy) 1.08 2016-06-21 4 D 0 125000 0.00 D 2015-08-21 2025-07-21 Common Stock 125000 0 D Stock Option (right to buy) 1.95 2016-06-21 4 D 0 35000 0.00 D 2016-04-28 2025-04-27 Common Stock 35000 0 D Stock Option (right to buy) 3.47 2016-06-21 4 D 0 15000 0.00 D 2013-07-26 2022-07-25 Common Stock 15000 0 D Stock Option (right to buy 3.47 2016-06-21 4 D 0 5000 0.00 D 2013-07-26 2022-07-25 Common Stock 5000 0 D Stock Option (right to buy) 4.42 2016-06-21 4 D 0 43750 0.00 D 2014-03-29 2024-05-20 Common Stock 43750 0 D Stock Option (right to buy) 4.57 2016-06-21 4 D 0 24000 0.00 D 2015-06-27 2024-06-26 Common Stock 24000 0 D Stock Option (right to buy) 15.30 2016-06-21 4 D 0 9999 0.00 D 2011-07-28 2021-07-27 Commmon Stock 9999 0 D Includes 6,250 previously reported shares issued as restricted stock units ("RSUs") under the Issuer's 2005 Equity Incentive Plan (the "Plan"). Per Section 3.4(b) of the Agreement and Plan of Merger, dated 5/9/16, among the Issuer, Grupo Ferrer Internactional, S.A. and Ferrer Pharma Inc. (the "Agreement), each RSU outstanding immediately prior to the Offer Closing (as defined in the Agreement) became fully vested immediately prior to the Offer Closing. Per the terms of the Agreement and the Offer (as defined in the Agreement), each share of the Issuer's common stock was tendered for $0.90 per share in cash, without interest and less any required withholding taxes, plus one contractual contingent value right per share ("CVR") (as defined in the Agreement). Disposed of per Section 3.4(a) of the Agreement, whereby each option that was outstanding immediately prior to the Offer Closing (as defined in the Agreement) was cancelled without consideration. /s/ Brent D. Fassett, as Attorney-in-Fact for Edwin S. Kamemoto 2016-06-21